secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001213900-24-050194
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Immunotherapeutics 2024 AGM: all director nominees elected, say-on-pay approved, annual frequency adopted
--------------------------------------------------------------------------------

- Director nominees Catherine Moukheibir (50.4M for) and Dr. Ramnik Xavier (53.9M for) elected; 4.24M broker non-votes.
- Baker Tilly ratified as independent auditor with 52.6M for vs 6.4M abstentions.
- Advisory vote on executive compensation passed with 54.7M for (99.99% of votes cast).
- Advisory vote on frequency: 54.2M chose 1 year; company will hold annual say-on-pay votes going forward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024050194/0001213900-24-050194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024050194/ea0207411-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-050194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer